ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Shionogi & Co., Ltd.

  • 5,761.00 JPY
  • -22.00
  • -0.38%
  • Japan
    Aug 21, 2019
  • Ticker
    TKS(4507)
  • Prev. close
    5,783
  • Market cap (JPY)
    1,831.97B
  • Market cap (USD)
    17,204.85M
  • Shares
    316.78M

Business Summary

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue363,721M3,279.87M
Gross Profit308,841M2,784.99M
Operating income138,538M1,249.27M
Income before tax170,343M1,536.07M
Net income132,759M1,197.16M
EBITDA157,737M1,422.40M
Diluted EPS420.663.79
Dividends Per Share940.84
Total Assets778,741M7,035.65M
Total liabilities106,308M960.45M
Total equity668,029M6,035.40M
Operating cash flow145,684M1,313.71M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 273,991M 309,973M 338,890M 344,667M 363,721M
Gross Profit 191,802M 235,215M 261,113M 270,756M 308,841M
Operating income 50,365M 91,406M 108,179M 115,219M 138,538M
Income before tax 82,051M 97,452M 122,695M 137,378M 170,343M
Net income 44,060M 66,687M 83,878M 108,866M 132,759M
EBITDA 66,016M 107,275M 124,519M 134,226M 157,737M
Diluted EPS 132.04 201.70 255.87 337.42 420.66
Dividends Per Share 52 62 72 82 94
Total Assets 602,900M 639,638M 670,271M 711,463M 778,741M
Total liabilities 124,017M 125,761M 144,058M 106,619M 106,308M
Total equity 474,530M 509,792M 522,737M 601,374M 668,029M
Operating cash flow 45,604M 102,290M 111,903M 129,790M 145,684M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 2,494.08M 2,581.29M 3,129.53M 3,109.80M 3,279.87M
Gross Profit 1,745.93M 1,958.74M 2,411.29M 2,442.93M 2,784.99M
Operating income 458.46M 761.18M 998.99M 1,039.57M 1,249.27M
Income before tax 746.89M 811.52M 1,133.04M 1,239.51M 1,536.07M
Net income 401.06M 555.33M 774.58M 982.25M 1,197.16M
EBITDA 600.92M 893.33M 1,149.89M 1,211.07M 1,422.40M
Diluted EPS 1.20 1.67 2.36 3.04 3.79
Dividends Per Share 0.47 0.51 0.66 0.73 0.84
Total Assets 5,027.30M 5,690.98M 6,015.17M 6,689.82M 7,035.65M
Total liabilities 1,034.12M 1,118.91M 1,292.81M 1,002.52M 960.45M
Total equity 3,956.88M 4,535.71M 4,691.16M 5,654.66M 6,035.40M
Operating cash flow 415.12M 851.81M 1,033.38M 1,171.04M 1,313.71M

Valuation Measures

Mar 2019
PER16.14
ROA17.81%
ROE20.91%
Operating margin38.08%
Profit margin36.50%

Key executives

  • President & Representative Director: Isao Teshirogi
  • Manager-Accounting & Finance: Kohji Hanasaki
  • Director & Vice President: Takuko Sawada
  • Executive Officer & Personnel Manager: Noriyuki Kishida
  • SVP-Pharmaceutical Research Division: Takeshi Shiota

Shareholders

  • Sumitomo Life Insurance Co. (5.8%)
  • Nomura Asset Management Co., Ltd. (5.6%)
  • Asset Management One Co., Ltd. (4.2%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
  • BlackRock Fund Advisors (3.3%)
  • Nikko Asset Management Co., Ltd. (3.0%)
  • Sumitomo Mitsui Banking Pension Fund (2.9%)
  • Nippon Life Insurance Co. (2.6%)
  • Daiwa Asset Management Co. Ltd. (2.5%)
  • The Vanguard Group, Inc. (2.3%)

Contact Details

Related Companies

  • Shionogi & Co. Restricted Stock Compensation Plan
  • Shionogi Healthcare & Co. Ltd.
  • Pionnier KK
  • Shionogi USA Holdings, Inc.
  • Beijing Shionogi Pharmaceutical Technology Ltd.
  • Shionogi Ltd.
  • Ezose Sciences, Inc.
  • Shionogi, Inc.
  • Shionogi Institute for Medical Science
  • Aburahi Laboratories
  • Taiwan Shionogi & Co. Ltd.
  • Shionogi Pharma Chemicals Co., Ltd.
  • Shionogi General Service Co., Ltd.
  • Shionogi Bunseki Center KK
  • Shionogi Ireland Ltd.
  • Shionogi Engineering Service Co. Ltd.
  • Shionogi Bioresearch Corp.
  • Shionogi & Co. Ltd. Pension Fund
  • Daiwa Trading Co., Ltd.
  • Soei Co., Ltd.
  • Tall Bridge, Inc.
  • C&O Pharmaceutical Technology (Holdings) Ltd.
  • QuatRx Pharmaceuticals Company
  • Shionogi Pharma, Inc.

Competitors

  • Gilead Sciences, Inc.
  • NanoViricides, Inc.
  • aTyr Pharma, Inc.
  • Vaxart, Inc.
  • TaiMed Biologics Inc.
  • KemPharm, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Iterum Therapeutics Plc
  • Achaogen, Inc.
  • Dova Pharmaceuticals, Inc.
  • Acura Pharmaceuticals, Inc.
  • Nektar Therapeutics
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Entasis Therapeutics Holdings, Inc.
  • Nabriva Therapeutics Plc
  • Progenics Pharmaceuticals, Inc.
  • Spero Therapeutics, Inc.
  • Tetraphase Pharmaceuticals, Inc.
Last Updated on 21 Aug, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media